INVENTING A NEW
                              ROADMAP FOR BIOTECH

                              Every day, we use our homegrown technologies to discover, develop, research and deliver new medicines that help people with serious diseases. Watch to see what drives us.

                              Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.

                              Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite? technologies, such as VelocImmune? which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

                              FOR 30 YEARS, OUR
                              MISSION HAS BEEN TO
                              USE THE POWER OF
                              SCIENCE TO BRING
                              NEW MEDICINES TO
                              PATIENTS... OVER
                              AND OVER AGAIN.

                              Neil Stahl, PhD, Executive VP,
                              Research and Development

                              2018 annual report PDF download

                              Check out our 2018 annual materials. The Responsibility Report and Annual Report are now online.

                              Read our annual report
                              and responsibility report

                              2018 responsibility report PDF download

                              REGENERON BY THE NUMBERS

                              • 30
                                years of scientific
                                leadership
                              • 8,100+
                                employees
                                worldwide
                              • 700+
                                employees with
                                an MD, PhD or
                                PharmD degree
                              • 6TH
                                consecutive year
                                in Forbes’ World’s
                                Most Innovative
                                Companies
                              • #1
                                ranking in Science
                                magazine’s global Top
                                Employer survey for six
                                of the past nine years
                              • 31,000+
                                employee volunteer hours
                                for 100+ organizations
                                in 2018
                              • 7
                                FDA-approved
                                medicines
                              • 98%
                                of our waste
                                diverted from
                                landfill, surpassing
                                our goal
                              • 100%
                                of drug candidates
                                invented and
                                developed in-house
                              • 800,000+
                                exomes sequenced
                                to date
                              • 100+
                                publications in 2018
                              • 20+
                                product candidates in
                                clinical development
                                across multiple
                                therapeutic areas
                              • Newsweek, America’s Most Responsible Companies, 2020

                                IDEA Pharma, Pharmaceutical Invention Index, 2019

                                RobecoSAM and S&P Dow Jones Indices: Dow Jones Sustainability World Index, 2019

                                Science: Top Employer, 2019

                                Harvard Business Review: Best Performing CEOs, 2019

                                Civic 50: Most Community-Minded Companies in the Nation, 2019

                              • Fast Company: Best Workplaces for Innovators, 2019

                                Shingo Institute: The Shingo Prize, 2019

                                Great Places to Work: Best Workplace in Ireland, 2019

                                Forbes: Top 10 Most Innovative Companies, 2018

                                Fortune: Best Companies to Work for, 2018

                              LEADERSHIP

                              We are the only biopharmaceutical company to be led by physician-scientists for more than 30 years. We consistently demonstrate our commitment to scientific excellence by counting multiple Nobel Laureates and five members of the National Academy of Sciences among our leadership, as well as being one of the first companies to form a Science and Technology Committee as an integral component of its Board, a practice which has since become industry standard.

                              Our leadership

                              A FOCUS
                              ON SCIENCE

                              From our first days, science has remained our central guiding principle.

                              Our journey

                              www,777788,coom